BALAXI PHARMACEUTICALS LIMITED has submitted to the Exchange, the financial results for the period ended March 31, 2026.
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Balaxi Pharmaceuticals reported FY2026 standalone revenue of Rs 8,085.11 lakhs (up 32.5% from Rs 6,098.82 lakhs) with net profit of Rs 514.69 lakhs (up 42.9% from Rs 360.13 lakhs). However, consolidated revenue declined to Rs 27,017.35 lakhs from Rs 29,256.12 lakhs (down 7.7%), with consolidated net profit falling sharply to Rs 141.69 lakhs from Rs 2,507.02 lakhs (down 94.4%). The company received its Manufacturing Licence for the Jadcherla pharmaceutical formulation facility on May 23, 2026, and is ready to launch Paracetamol and Piroxicam products commercially. WHO-GMP certification is in progress. The Board also re-appointed internal auditors and recommended Ms. Akshita Ostwal for a second term as Independent Director. Auditors issued clean (unmodified) opinions for both standalone and consolidated financials.
The standalone business shows strong growth, but the significant decline in consolidated revenue and sharp drop in consolidated profit due to subsidiary losses is a major concern for shareholders. The new manufacturing licence is a positive development for future revenue diversification.